Search results for "membrane"

showing 10 items of 4477 documents

Clarithromycin in the Management of Chronic Rhinosinusitis: Preliminary Results of a Possible Its New Use

2018

The aim of this study is to evaluate the efficacy and safety of prolonged therapy with low-dose clarithromycin in patients with chronic rhinosinusitis with polyps (CRSwP) after endoscopic sinus surgery (ESS). A total of 10 patients with CRSwP were identified and subjected to bilateral ESS. In post-operative patients they were treated with nasal wash with saline solution and steroid sprays (beclomethasone). During follow-up, after 30–40 days after the operation (M = 35.4 SD = +4.33), patients reported a worsening of symptoms with onset of nasal obstruction; reduction/loss of smell; headache; onset of viscous secretions and therefore all patients continued therapy with saline nasal irrigation…

medicine.medical_specialtymedicine.medical_treatmentMucous membrane of noseEosinophilGastroenterology03 medical and health sciences0302 clinical medicineHyposmiaEdemaInternal medicineClarithromycinClarithromycinmedicineChronic rhinosinusitis with polyp030223 otorhinolaryngologyTopical Steroid TherapySalineNosebusiness.industryOtorhinolaryngology2734 Pathology and Forensic MedicineChronic rhinosinusitis with polypsSurgerymedicine.anatomical_structureOtorhinolaryngologyOtorhinolaryngology030220 oncology & carcinogenesisOriginal ArticleSurgeryChronic rhinosinusitis with polyps; Clarithromycin; Eosinophilmedicine.symptombusinessmedicine.drug
researchProduct

Survival with low- and high-flux dialysis

2021

The National Program of I + D + I 2008–2011 and Instituto de Salud Carlos III (ISCIII), the ISCIII Retic REDinREN (RD06/0016/1013, RD12/0021/0023 and RD16/ 0009/0017), the ISCIII (ICI14/00107, PI17/00384 and PI20/00633), Fondo Europeo de Desarrollo Regional (FEDER), Plan Estatal de I + D + I 2013–2016, Plan de Ciencia, Tecnología e Innovación 2013–2017 y 2018–2022 del Principado de Asturias (GRUPIN14-028, IDI-2018-000152) (...)

medicine.medical_specialtymedicine.medical_treatmentPopulation030232 urology & nephrology610030204 cardiovascular system & hematologyPeritoneal dialysis03 medical and health sciences0302 clinical medicineInternal medicinemedicineddc:610AcademicSubjects/MED00340educationDialysisTransplantationeducation.field_of_studychronic haemodialysisbusiness.industryMortality rateHazard ratioOriginal ArticlesmortalityNephrologyRelative riskPropensity score matchingdialysismortality riskHemodialysisbusinessdialysis membranes
researchProduct

Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy

2020

Abstract Purpose To report a female patient of biclonal Lewis syndrome which consists of a trias: biclonal gammopathy of undetermined significance, paraproteinemic keratopathy in form of a brownish discoid opacification at the level of Descemet's membrane and hypercupremia. After several years there was a conversion to multiple myeloma. Systemic chemotherapy led to a complete remission of multiple myeloma and to a normalization of the copper level in the blood that lasted five years. The corneal opacification remained unchanged. Observations A currently 66-year-old woman suffered from biclonal Lewis syndrome. On both eyes there is a central discoid yellow-brownish discoloration in the Pre-D…

medicine.medical_specialtymedicine.medical_treatmentUnchanged corneal opacity after chemotherapyGastroenterology03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyChemotherapy-induced normal level of copper in serumInternal medicineMedicineAffinity of IgG to copper in Lewis syndromeCopper levelsProgressive anemiaMultiple myelomaLewis syndromeHypercupremiaChemotherapyBiclonal gammopathybusiness.industrySystemic chemotherapyHypercupremiaCorneal opacitymedicine.diseaseOphthalmologylcsh:RE1-994030221 ophthalmology & optometrybusinessDiscoid brownish opacification of Descemet membrane030217 neurology & neurosurgeryAmerican Journal of Ophthalmology Case Reports
researchProduct

Diuretic Strategies in Acute Heart Failure and Renal Dysfunction: Conventional vs Carbohydrate Antigen 125-guided Strategy. Clinical Trial Design

2017

Abstract Introduction and objectives The optimal treatment of patients with acute heart failure (AHF) and cardiorenal syndrome type 1 (CRS-1) is far from being well-defined. Arterial hypoperfusion in concert with venous congestion plays a crucial role in the pathophysiology of CRS-I. Plasma carbohydrate antigen 125 (CA125) has emerged as a surrogate of fluid overload in AHF. The aim of this study was to evaluate the clinical usefulness of CA125 for tailoring the intensity of diuretic therapy in patients with CRS-1. Methods Multicenter, open-label, parallel clinical trial, in which patients with AHF and serum creatinine ≥ 1.4 mg/dL on admission will be randomized to: a) standard diuretic str…

medicine.medical_specialtymedicine.medical_treatmentWater-Electrolyte ImbalanceRenal functionCardiorenal syndrome030204 cardiovascular system & hematologyPatient Care Planning03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFurosemideInternal medicineHumansMedicine030212 general & internal medicineDiureticsIntensive care medicineHeart FailureCreatinineCardio-Renal Syndromebusiness.industryClinical study designChlorthalidoneMembrane ProteinsGeneral Medicinemedicine.diseasePathophysiologyAcetazolamideClinical trialchemistryCA-125 AntigenCreatinineHeart failureAcute DiseaseCardiologyDiureticbusinessRevista Española de Cardiología (English Edition)
researchProduct

Bortezomib Induces Anti–Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation

2021

Abstract The proteasome inhibitor bortezomib induces apoptosis in multiple myeloma cells and has transformed patient outcome. Using in vitro as well as in vivo immunodeficient and immunocompetent murine multiple myeloma models, we here show that bortezomib also triggers immunogenic cell death (ICD), characterized by exposure of calreticulin on dying multiple myeloma cells, phagocytosis of tumor cells by dendritic cells, and induction of multiple myeloma–specific immunity. We identify a bortezomib-triggered specific ICD gene signature associated with better outcome in two independent cohorts of patients with multiple myeloma. Importantly, bortezomib stimulates multiple myeloma cell immunogen…

medicine.medical_treatmentIFNBortezomibMiceImmune systemimmune system diseaseshemic and lymphatic diseasesimmunogenic cell deathmedicineAnimalsHumansbortezomib myelomaMultiple myelomaBortezomibbusiness.industryImmunityMembrane ProteinsGeneral MedicineImmunotherapymedicine.diseaseNucleotidyltransferasesStingApoptosisCancer researchProteasome inhibitorImmunogenic cell deathMultiple MyelomabusinessSignal TransductionSTINGmedicine.drugBlood Cancer Discovery
researchProduct

Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts

1995

OBJECTIVES--To investigate the influence of the Th1 and Th2 lymphokines interleukins (IL)-4 and IL-13, interferon gamma (IFN gamma), and several monokines on the adhesion of mononuclear cells to synovial fibroblasts and intercellular adhesion molecule-1 (ICAM-1) expression and cytokine production of synovial fibroblasts in patients with osteoarthritis. METHODS--Synovial fibroblasts were isolated from patients with osteoarthritis and stimulated with IL-1 beta, IL-4, IL-6, IL-10, IL-12, IL-13, tumour necrosis factor alpha (TNF alpha), and IFN gamma. Subsequently, we determined the production of IL-1 alpha, IL-1 beta, IL-6, IL-10, IL-12, IFN alpha and TNF alpha, and the expression of ICAM-1 ly…

medicine.medical_treatmentImmunologyIntercellular Adhesion Molecule-1BiologyGeneral Biochemistry Genetics and Molecular BiologyTh2 CellsRheumatologyOsteoarthritisCell AdhesionmedicineHumansImmunology and AllergyInterferon gammaCell adhesionCells CulturedInterleukin-13Interleukin-6Cell adhesion moleculeSynovial MembraneLymphokineReceptors InterleukinFibroblastsTh1 CellsIntercellular Adhesion Molecule-1Molecular biologyRecombinant ProteinsReceptors Interleukin-4Cytokinemedicine.anatomical_structureImmunologyCytokinesTumor necrosis factor alphaInterleukin-4Synovial membraneResearch Articlemedicine.drug
researchProduct

A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase

2002

Abstract In a previous study, we reported a new pyrroloquinazoline derivative, 3-(4′-acetoxy-3′,5′-dimethoxy)benzylidene-1,2-dihydropyrrolo[2,1- b ]quinazoline-9-one (PQ), which inhibited human purified 5-lipoxygenase activity and prostaglandin E 2 release in lipopolysaccharide-stimulated RAW 264.7 cells. In the present work, we show that PQ inhibits cyclo-oxygenase-2 activity in intact cell assays (human monocytes) and purified enzyme preparations (ovine isoenzymes) without affecting cyclo-oxygenase-1 activity. This behaviour was confirmed in vivo by using the zymosan-injected mouse air pouch model, where PQ caused a marked reduction in cell migration and leukotriene B 4 levels at 4 h, as …

medicine.medical_treatmentPharmacologyMonocytesMicechemistry.chemical_compoundIn vivomedicineAnimalsEdemaHumansCyclooxygenase InhibitorsPyrrolesLipoxygenase InhibitorsEnzyme InhibitorsProstaglandin E2Pain MeasurementPharmacologyAnalgesicsArachidonate 5-LipoxygenaseSheepCyclooxygenase 2 InhibitorsDose-Response Relationship DrugbiologyChemistryAnti-Inflammatory Agents Non-SteroidalZymosanMembrane ProteinsBiological activityIsoenzymesBiochemistryMechanism of actionCyclooxygenase 2Prostaglandin-Endoperoxide SynthasesEnzyme inhibitorArachidonate 5-lipoxygenaseQuinazolinesQuinolinesbiology.proteinFemalemedicine.symptomProstaglandin Emedicine.drug
researchProduct

A single mutation in the recombinant light chain of tetanus toxin abolishes its proteolytic activity and removes the toxicity seen after reconstituti…

1994

Specific proteolysis by the tetanus toxin light chain of a vesicle-associated membrane protein (VAMP) involved in exocytosis is thought to underlie its intracellular blockade of neurotransmitter release. To substantiate this mechanism, recombinant light chain was expressed as a maltose binding protein-light chain fusion product in Escherichia coli. After purification of affinity chromatography and cleavage with factor Xa, the resultant light chain was isolated and its identity confirmed by Western blotting and N-terminal sequencing. It exhibited activity similar to that of the native light chain in proteolyzing its target in isolated bovine small synaptic vesicles and in hydrolyzing a 62-re…

medicine.medical_treatmentRecombinant Fusion ProteinsMolecular Sequence DataNeurotoxinsGlutamic AcidMaltose bindingNerve Tissue ProteinsIn Vitro TechniquesImmunoglobulin light chainBiochemistrySynaptic vesicleExocytosislaw.inventionR-SNARE ProteinsMiceStructure-Activity RelationshipAffinity chromatographyGlutamatesTetanus ToxinlawThermolysinEndopeptidasesmedicineEscherichia coliAnimalsAmino Acid SequenceProteaseBase SequenceChemistryMembrane ProteinsMolecular biologyPeptide FragmentsRecombinant DNAMutagenesis Site-DirectedCattleBiochemistry
researchProduct

Cancer-Initiating Cells from Colorectal Cancer Patients Escape from T Cell-Mediated Immunosurveillance In Vitro through Membrane-Bound IL-4

2014

Abstract Cancer-initiating cells (CICs) that are responsible for tumor initiation, propagation, and resistance to standard therapies have been isolated from human solid tumors, including colorectal cancer (CRC). The aim of this study was to obtain an immunological profile of CRC-derived CICs and to identify CIC-associated target molecules for T cell immunotherapy. We have isolated cells with CIC properties along with their putative non-CIC autologous counterparts from human primary CRC tissues. These CICs have been shown to display “tumor-initiating/stemness” properties, including the expression of CIC-associated markers (e.g., CD44, CD24, ALDH-1, EpCAM, Lgr5), multipotency, and tumorigenic…

medicine.medical_treatmentT cellT-LymphocytesImmunologyTumor initiationCell CommunicationLymphocyte ActivationArticleImmune systemAntigenAntigens NeoplasmCell Line TumorSpheroids CellularmedicineTumor Cells CulturedImmunology and AllergyHumansImmunologic SurveillanceInterleukin 4Settore MED/04 - Patologia GeneralebiologyCD44Cell MembraneImmunotherapyImmunosurveillancemedicine.anatomical_structureImmunologybiology.proteinNeoplastic Stem CellsTumor EscapeInterleukin-4Colorectal NeoplasmsIL-4 Cancer-initiating cells (CICs)
researchProduct

Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Sin…

2021

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the rescue treatment proposed to patients with refractory cardiogenic shock. The VA-ECMO implantation promotes inflammation and ischemia-reperfusion injuries through the VA-ECMO flow, causing digestive mucosa barrier disrupture and inducing translocation of bacterial wall components—Lipopolysaccharides (LPS) with further inflammation and circulatory impairment. LPS is a well-studied surrogate indicator of bacterial translocation. Oxiris membrane is a promising and well-tolerated device that can specifically remove LPS. The main study aim is to compare the LPS elimination capacity of Oxiris membrane vs. a non-absorban…

medicine.medical_treatmentcontinuous renal replacement therapyheart failureoxirisContext (language use)InflammationCardiovascular Medicineartificial membranelaw.inventionStudy ProtocolRandomized controlled triallawmedicineClinical endpointExtracorporeal membrane oxygenationDiseases of the circulatory (Cardiovascular) systemRenal replacement therapycytokines/bloodbusiness.industryCardiogenic shockcardiogenic shockextracorporeal membrane oxygenationmedicine.diseasesurgical procedures operativeendotoxin/bloodRC666-701AnesthesiaHeart failuremedicine.symptomCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct